Literature DB >> 1763661

Longitudinal studies of mild primary hyperparathyroidism.

S Ljunghall1, S Jakobsson, C Joborn, M Palmér, J Rastad, G Akerström.   

Abstract

In 1969, a health survey was offered to all inhabitants of a town district in Sweden. A clinical examination was carried out, and among other variables, a measurement was made of serum calcium. The same procedure was repeated in 1971. From these two investigations a cohort of 176 individuals (1.1%) with sustained hypercalcemia was identified who could be followed during the subsequent 15 years. Comparisons were made with an age- and sex-matched control group from the same health survey. Survival was significantly lower in the hypercalcemic cohort than in the control group. This reduction was related to the degree of hypercalcemia and apparently mainly due to diseases of the circulatory organs. There was no marked deterioration of renal function, and although there was in some patients a moderate progression of the hypercalcemia, none developed a hypercalcemic crisis during 15 years of follow-up. In consecutively referred patients with primary hyperparathyroidism, psychiatric disturbances of mainly a depressive character were found upon detailed analysis within a majority of the patients, and parathyroid surgery resulted in a clear improvement in mental health.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763661     DOI: 10.1002/jbmr.5650061423

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

1.  Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism.

Authors:  E Lundgren; E Szabo; S Ljunghall; R Bergström; L Holmberg; J Rastad
Journal:  BMJ       Date:  1998-09-26

2.  Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden.

Authors:  Helene Siilin; Ewa Lundgren; Hans Mallmin; Dan Mellström; Claes Ohlsson; Magnus Karlsson; Eric Orwoll; Osten Ljunggren
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

3.  Improving diagnostic recognition of primary hyperparathyroidism with machine learning.

Authors:  Yash R Somnay; Mark Craven; Kelly L McCoy; Sally E Carty; Tracy S Wang; Caprice C Greenberg; David F Schneider
Journal:  Surgery       Date:  2016-12-15       Impact factor: 3.982

4.  [Hypercalcemic crisis].

Authors:  J Pfeilschifter
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

Review 5.  Cardiovascular aspects of primary hyperparathyroidism.

Authors:  M D Walker; S J Silverberg
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 6.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

7.  Normocalcemia and persistent elevated serum concentrations of 1-84 parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of increased morbidity from cardiovascular disease.

Authors:  Henrik Vestergaard; Lars ØStergaard Kristensen
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

Review 8.  Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta-Analysis.

Authors:  Donald J McMahon; Angela Carrelli; Nick Palmeri; Chiyuan Zhang; Marco DiTullio; Shonni J Silverberg; Marcella D Walker
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

9.  The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?

Authors:  Monica S Eigelberger; W Keat Cheah; Philip H G Ituarte; Leanne Streja; Quan-Yang Duh; Orlo H Clark
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

Review 10.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Shonni J Silverberg; E Michael Lewiecki; Leif Mosekilde; Munro Peacock; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.